on Theranexus (EPA:ALTHX)
Theranexus: 2024 Annual Review and New Perspectives
On April 29, 2025, biopharmaceutical company Theranexus announced its 2024 financial results. Revenue remained flat, with operating income of €2,296k, mostly from grants. Operating expenses fell 38% to €4,922k, thanks to a drop in R&D spending. Net income increased but remains negative at -€1,765k.
Theranexus has suspended its financing line with IRIS, expressing confidence in its future partnerships. The agreement with Exeltis for TX01 generated €2 million. In R&D, the Batten-1 candidate achieved positive results. Cash at the end of March 2025 stands at €2.9 million, with visibility through June 2026.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news